Published by: Kowsar
Corrected Proof scheduled for 6 (2)

Methadone Maintenance Therapy (MMT) Clients Should Be More Noticed for Hepatitis C Elimination in Iran

Hamidreza Karimi-Sari 1 , 2 , 3 and Seyed Moayed Alavian 2 , 3 , *
Authors Information
1 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran
Article information
  • Thrita: , In Press (In Press); e57840
  • Published Online: June 30, 2017
  • Article Type: Letter
  • Received: April 5, 2017
  • Accepted: May 3, 2017
  • DOI: 10.5812/thrita.57840

To Cite: Karimi-Sari H, Alavian S M. Methadone Maintenance Therapy (MMT) Clients Should Be More Noticed for Hepatitis C Elimination in Iran, Thrita. Online ahead of Print ;In Press(In Press):e57840. doi: 10.5812/thrita.57840.

Copyright © 2017, Thrita Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
  • 1. Abousaidi H, Rezahosseini O, Bidaki R, Fathollahi MS, Nejad HRG, Shahi GHH, et al. Viral and Psychiatric Disorders in Methadone Maintenance Therapy (MMT) Clients. Thrita. 2016;5(4).
  • 2. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016;16(4). e37089. doi: 10.5812/hepatmon.37089. [PubMed: 27275164].
  • 3. Lancet T. Towards elimination of viral hepatitis by 2030. Elsevier; 2016.
  • 4. Polaris Observatory H. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76. doi: 10.1016/S2468-1253(16)30181-9. [PubMed: 28404132].
  • 5. Mirminachi B, Mohammadi Z, Merat S, Neishabouri A, Sharifi AH, Alavian SH, et al. Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analysis. Hepat Mon. 2017;17(2). doi: 10.5812/hepatmon.42291.
  • 6. Malekinejad M, Navadeh S, Lotfizadeh A, Rahimi-Movaghar A, Amin-Esmaeili M, Noroozi A. High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012). Int J Infect Dis. 2015;40:116-30. doi: 10.1016/j.ijid.2015.09.022. [PubMed: 26460088].
  • 7. Hajarizadeh B. Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran. Hepat Mon. 2017;17(1). doi: 10.5812/hepatmon.45788.
  • 8. Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16(8). doi: 10.5812/hepatmon.guideline.

Cited By:


Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:


  • Hamidreza Karimi-Sari: [PubMed] []
  • Seyed Moayed Alavian: [PubMed] []

Readers' Comments